BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of
BALA CYNWYD, Pa., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to...
Stay updated with breaking news from Taro Board. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BALA CYNWYD, Pa., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to...
Taro Pharmaceutical Industries Ltd. today provided unaudited financial results for the quarter and six months ended September 30, 2023. Quarter ended September 30, 2023 Highlights ─ compared to...
Sun Pharma is looking to fully acquire its Israel-based unit Taro Pharmaceutical Industries in order to integrate the dermatology business with itself and keep it profitable amid increasing competition in the segment, according to Managing Director Dilip Shanghvi. The Mumbai-based drug major has proposed to fully acquire Taro through a reverse triangular merger.
The company has issued a letter to the Taro board with a proposal containing a non-binding indication of interest to acquire all of the outstanding ordinary shares for a purchase price of USD 38 per ordinary share in cash.